[go: up one dir, main page]

WO2002044360A3 - Arginine deiminase modifiee - Google Patents

Arginine deiminase modifiee Download PDF

Info

Publication number
WO2002044360A3
WO2002044360A3 PCT/US2001/029184 US0129184W WO0244360A3 WO 2002044360 A3 WO2002044360 A3 WO 2002044360A3 US 0129184 W US0129184 W US 0129184W WO 0244360 A3 WO0244360 A3 WO 0244360A3
Authority
WO
WIPO (PCT)
Prior art keywords
arginine deiminase
modified arginine
methods
modified
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/029184
Other languages
English (en)
Other versions
WO2002044360A2 (fr
Inventor
Mike A Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenix Pharmacologics Inc
Original Assignee
Phoenix Pharmacologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/723,546 external-priority patent/US6737259B1/en
Application filed by Phoenix Pharmacologics Inc filed Critical Phoenix Pharmacologics Inc
Priority to JP2002546708A priority Critical patent/JP2004515232A/ja
Priority to KR10-2003-7007054A priority patent/KR20040004449A/ko
Priority to CA002430077A priority patent/CA2430077A1/fr
Priority to AU2001289132A priority patent/AU2001289132A1/en
Priority to EP01968928A priority patent/EP1337630A2/fr
Publication of WO2002044360A2 publication Critical patent/WO2002044360A2/fr
Publication of WO2002044360A3 publication Critical patent/WO2002044360A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

L'invention concerne une arginine déiminase modifiée avec du glycol polyéthylénique, des méthodes de traitement du cancer, et des méthodes de traitement et/ou d'inhibition de métastase.
PCT/US2001/029184 2000-11-28 2001-09-19 Arginine deiminase modifiee Ceased WO2002044360A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002546708A JP2004515232A (ja) 2000-11-28 2001-09-19 修飾されたアルギニンデイミナーゼ
KR10-2003-7007054A KR20040004449A (ko) 2000-11-28 2001-09-19 변형된 아르기닌 데이미나제
CA002430077A CA2430077A1 (fr) 2000-11-28 2001-09-19 Arginine deiminase modifiee
AU2001289132A AU2001289132A1 (en) 2000-11-28 2001-09-19 Modified arginine deiminase
EP01968928A EP1337630A2 (fr) 2000-11-28 2001-09-19 Arginine deiminase modifiee

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/723,546 2000-11-28
US09/723,546 US6737259B1 (en) 1997-05-12 2000-11-28 Modified arginine deiminase

Publications (2)

Publication Number Publication Date
WO2002044360A2 WO2002044360A2 (fr) 2002-06-06
WO2002044360A3 true WO2002044360A3 (fr) 2002-12-19

Family

ID=24906720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029184 Ceased WO2002044360A2 (fr) 2000-11-28 2001-09-19 Arginine deiminase modifiee

Country Status (7)

Country Link
EP (1) EP1337630A2 (fr)
JP (1) JP2004515232A (fr)
KR (1) KR20040004449A (fr)
CN (1) CN1518595A (fr)
AU (1) AU2001289132A1 (fr)
CA (1) CA2430077A1 (fr)
WO (1) WO2002044360A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
WO2004000349A1 (fr) * 2002-06-20 2003-12-31 Bio-Cancer Treatment International Limited Preparation pharmaceutique et methode de traitement de tumeurs malignes chez l'etre humain par privation d'arginine
WO2004046309A2 (fr) * 2002-11-18 2004-06-03 Phoenix Pharmacologics, Inc. Methodes d'inhibition d'une replication virale in vivo
WO2005107815A2 (fr) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Dérivés de polymères comprenant un point de ramification de type imide
WO2006015512A1 (fr) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Arginine déiminase modifiée
FR2884717B1 (fr) * 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101812438B (zh) * 2010-03-25 2014-08-27 江苏泰康生物医药有限公司 一种精氨酸脱亚氨酶突变体及其制备与应用
CN102703339B (zh) * 2011-08-29 2013-08-14 山东恩贝生物工程有限公司 高产精氨酸脱亚胺酶菌株及用它生产l-瓜氨酸的方法
KR101638226B1 (ko) 2012-04-04 2016-07-08 폴라리스 그룹 아르기닌 디이미나아제를 사용한 치료 방법
SG11201507354QA (en) 2013-03-15 2015-10-29 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
EP3119421B1 (fr) * 2014-03-18 2019-10-02 TDW Group Adi pégylée chimères manipulée et procédés d'utilisation
EP3193913B1 (fr) 2014-09-16 2022-05-11 Polaris Group Arginine déiminase à réactivité croisée réduite vis-à-vis d'anticorps anti-adi-peg 20 pour le traitement du cancer
ES2905716T3 (es) * 2016-09-29 2022-04-11 Meharry Medical College Péptidos derivados de la arginina deiminasa de S. cristatus como inhibidores bacterianos
EP3534963B1 (fr) * 2016-11-02 2024-04-17 Polaris Group Formulations d'arginine déiminase pegylée
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN106591270B (zh) * 2017-01-23 2018-09-21 江南大学 一株定点突变改造的基因工程精氨酸脱亚胺酶
SG11202004965RA (en) * 2017-11-30 2020-06-29 Jazz Pharmaceuticals Ireland Ltd Methods of treatment with asparaginase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04121187A (ja) * 1990-09-10 1992-04-22 Nikko Kyodo Co Ltd ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
WO1998051784A1 (fr) * 1997-05-12 1998-11-19 Phoenix Pharmacologics, Inc. Arginine deiminase modifiee
US6132713A (en) * 1997-01-31 2000-10-17 Enzon, Inc. Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04121187A (ja) * 1990-09-10 1992-04-22 Nikko Kyodo Co Ltd ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US6132713A (en) * 1997-01-31 2000-10-17 Enzon, Inc. Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same
WO1998051784A1 (fr) * 1997-05-12 1998-11-19 Phoenix Pharmacologics, Inc. Arginine deiminase modifiee

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI, Hinxton, UK; 16 December 1997 (1997-12-16), FRASER, C ET AL.: "Borrelia burgdorferi (section 69 of 70) of the complete genome.", XP002211866, Database accession no. AE001183 *
DATABASE WPI Section Ch Week 200161, Derwent World Patents Index; Class A96, AN 1992-188063, XP002211867 *
KNODLER LEIGH A ET AL: "Cloning and expression of a prokaryotic enzyme, arginine deiminase, from a primitive eukaryote Giardia intestinalis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 8, 20 February 1998 (1998-02-20), pages 4470 - 4477, XP002211868, ISSN: 0021-9258 *
TAKAKU H ET AL: "Anti-tumor activity of arginine deiminase from mycoplasma arginini and its growth-inhibitory mechanism", JAPANESE JOURNAL OF CANCER RESEARCH, AMSTERDAM, NL, vol. 86, no. 9, 1 September 1995 (1995-09-01), pages 840 - 846, XP002092819 *
TAKAKU HARUO ET AL: "Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini.", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 84, no. 11, 1993, pages 1195 - 1200, XP008007607, ISSN: 0910-5050 *

Also Published As

Publication number Publication date
AU2001289132A1 (en) 2002-06-11
KR20040004449A (ko) 2004-01-13
WO2002044360A2 (fr) 2002-06-06
JP2004515232A (ja) 2004-05-27
EP1337630A2 (fr) 2003-08-27
CN1518595A (zh) 2004-08-04
CA2430077A1 (fr) 2002-06-06

Similar Documents

Publication Publication Date Title
EP0981607A4 (fr) Arginine deiminase modifiee
WO2002044360A3 (fr) Arginine deiminase modifiee
WO2002071928A3 (fr) Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
NO20015462L (no) Anvendelse av fthalazinderivater
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
WO2004005472A3 (fr) Inhibiteurs de ftsz et leurs utilisations
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
WO2002004562A3 (fr) Capteurs de metal a base de fluoresceine et procedes de fabrication et utilisation des memes
WO2005108565A3 (fr) Enzymes modifiees, procedes de production d'enzymes modifiees et utilisations de ces dernieres
WO2001094636A8 (fr) Compositions, trousses et procedes d'identification et de modulation du diabete de type i
WO2001018542A3 (fr) Compositions, trousses et methodes pour l'identification, l'analyse, la prevention et la therapie du cancer des ovaires
WO2000053776A3 (fr) Nouveaux genes humains du type kallikreine
AU2001267428A1 (en) Direct detection of individual molecules
WO2001051523A3 (fr) Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
WO2001042792A3 (fr) Compositions, kits, et methodes d'identification, d'evaluation, de prevention, et de therapie du cancer du col de l'uterus
YU68900A (sh) Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka
AU2001270912A1 (en) Improvements relating to the security of authentication systems
WO2003035889A3 (fr) Compositions et procedes permettant de detecter des bacteries
AU2002220697A1 (en) Isolated luciferases lu164, lual and lu22, and the use of the same
AU2002212678A1 (en) Methods of quantitative detection of genetic recombinants and standard molecules for the methods.
WO2006015191A3 (fr) Analogues de lonidamine multicycliques
WO2002044419A3 (fr) Analyse d'expression d'acides nucleiques kiaa et polypeptides utilises dans le diagnostic et le traitement du cancer de la prostate
WO2001082972A3 (fr) Compositions comportant des vehicules et des complexes transportables
EP1686122A4 (fr) Antitumoral

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002546708

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2430077

Country of ref document: CA

Ref document number: 2001289132

Country of ref document: AU

Ref document number: 1020037007054

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 01819673X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001968928

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001968928

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037007054

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001968928

Country of ref document: EP